Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ACP3 | P15309 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9026172 | 0.87 | TSHR (0.59) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL254876 | 0.85 | TSHR (0.61) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL3642758 | 0.85 | TSHR (0.61) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL7788899 | 0.82 | TSHR (0.53) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL27965075 | 0.82 | TSHR (0.53) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL6359586 | 0.81 | TSHR (0.57) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL2433538 | 0.81 | TSHR (0.57) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL2545597 | 0.81 | MEN1 (0.61) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL10654030 | 0.81 | TSHR (0.57) | TSHRLMNAKMT2AMEN1HPGD | |
| SCHEMBL2540712 | 0.81 | TSHR (0.57) | TSHRLMNAKMT2AMEN1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115066428-B | Boric acid derivatives | 首药控股(北京)股份有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-105980381-A | Substituted uracils and use thereof | 拜耳医药股份有限公司 | 2016-09-28 | — | — | CN | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| US-20100056524-A1 | Compound | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-03-04 | — | — | US | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009122180-A1 | PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES | MEDICAL RESEARCH COUNCIL (GB) | 2009-10-08 | — | — | WO | disclosed |
| CN-1028864-C | Macrolide compounds and their preparation | SANKYO CO (JP) | 1995-06-14 | — | — | CN | disclosed |
| CN-1022834-C | Macrolide compounds, their preparation and their use | SANKYO CO (JP) | 1993-11-24 | — | — | CN | disclosed |
| CN-1071430-A | Macrolide bonded preparation method | SANKYO CO (JP) | 1993-04-28 | — | — | CN | disclosed |
| CN-87103559-A | Macrolide compounds, their production and use | — | 1988-01-27 | — | — | CN | disclosed |
| US-4436751-A | Nitrobenzyl monates antibacterial compounds | BEECHAM GROUP LIMITED (GB) | 1984-03-13 | — | — | US | disclosed |
| US-4348223-A | FOR PREEMERGENT AND POSTEMERGENT APPLICATION | PPG INDUSTRIES, INC. (US) | 1982-09-07 | — | — | US | disclosed |
| EP-0055616-A1 | Antibacterial compounds | BEECHAM GROUP PLC (GB) | 1982-07-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056524-A1 | Compound | NR3C2, NR3C1, NR2E3 | TSHR 133/4885LMNA 4683/4885KMT2A 3200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.